Benchmark Reiterates Buy on Belite Bio, Maintains $57 Price Target
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Bruce Jackson has reiterated a 'Buy' rating on Belite Bio (NASDAQ:BLTE) and maintained a price target of $57.

November 07, 2023 | 5:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Belite Bio's stock rating has been reiterated as 'Buy' by Benchmark analyst Bruce Jackson, with a maintained price target of $57.
The reiteration of a 'Buy' rating by a Benchmark analyst indicates a positive outlook for the company's stock. The maintained price target of $57 suggests that the analyst believes the stock is undervalued at its current price, which could lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100